european psychiatric association

Addictive Behaviours

Section committee

DOM Geert , Chair

KIEFER Falk, Co-Chair

SCHELLEKENS Arnt, Secretary


Aims & Objectives

Section objectives

  1. To raise awareness about the relevance of substance misuse issues for other Sections of the European Psychiatric Association
  2. To enhance understanding of the mechanisms underlying addictive behaviour
  3. To understand the social context of the development of addictive behaviour with particular attention to ’special’ groups including women, older people, ethnic minorities
  4. To improve psychological and pharmacological treatment interventions for addicted individuals
  5. To develop appropriate delivery of interventions within a service framework
  6. To assess specific needs of migrants with addictive disorders and to provide skills in transcultural assessment and intercultural therapy of addictive disorders
  7. To develop and deliver training courses for undergraduate, postgraduate and continuing professional development
  8. To compare and contrast clinical service, training, research and policy across Europe
  9. To develop a network of practitioners and scientists for exchange of ideas, policy development and for the evolution of research
  10. To advocate for patients with addiction problems

Activities

Meetings/events

ECP Clinical Case Discussion: Alcohol Use Disorders at EPA 2019

ECP Clinical Case Discussion: Alcohol Use Disorders at EPA 2019
Description :

Of the Eastern European countries, former Soviet Union economies have the highest rates of alcohol consumption and male mortality in the world. The World Health Organization data show that of the 15 countries with the largest life-expectancy gap between men and women, ten are former Soviet Union and Eastern European economies. Excessive alcohol consumption has a high correlation with this extremely high rates of male mortality. It is also known that among the countries with a population of more than half million people, 11 out of 15 with the highest level of consumption of spirits are Eastern European and former Soviet Union countries, of which Belarus and Russia are ranked first and second respectively. Epidemiological studies estimate that the prevalence of binge drinking among drinkers in the past 12 months is the highest in Africa, Russian Federation, Eastern Mediterranean and South-East Asia regions, and has a 3-4-fold higher prevalence in comparison to the alcohol dependence syndrome. Among the individuals who frequently practice binge drinking, there is a 13-fold or 19-fold increase in the risk of being classified as an alcohol-abusing or alcohol-dependent person, respectively. Therefore, the optimal anti-alcohol therapeutic strategies should target not only alcohol dependent persons but also the binge drinking population to facilitate discontinuation of alcohol consumption and block its possible progression to the alcohol dependence.

Date :
april 7th, 2019

Treatment of Comorbid Psychiatric Disorders: How Do We Deal With Addiction? at EPA 2019

Treatment of Comorbid Psychiatric Disorders: How Do We Deal With Addiction? at EPA 2019
Description :

Psychiatric comorbidity, in which multiple psychiatric disorders occur simultaneously, is rather the rule than the exception in the clinical practice. Depression, anxiety, psychosis, attention deficit hyperactivity disorders and addiction are the most common psychiatric disorders, and lead the global burden and socio-economic impact of mental disorders worldwide. These mental illnesses often co-occur, and present overlapping symptom profiles. Psychiatric comorbidity precipitates symptom severity, relapses and suicide rates. In addition, treatment approaches are less effective, which often leads to severe illness and burden for patients, families and society. Despite the high rates of comorbidity, current guidelines often do not consider treatment strategies for comorbid substance use disorders. In this workshop, we will discuss the diagnostic and treatment aspects of comorbid substance use disorders with mood, anxiety, psychotic, attention deficit hyperactivity disorders. Practical clinical approaches, recent developments and the most updated guidelines will be briefly presented by the appointed speakers. After that, an interactive discussion with the audience will follow, using clinical cases to exemplify evidence-based decision making in psychiatric comorbidity.

Date :
April 7th, 2019

New Treatment Targets in Addiction Psychiatry: Translating Neuromodulation to the Clinic, at EPA 2019

New Treatment Targets in Addiction Psychiatry: Translating Neuromodulation to the Clinic, at EPA 2019
Description :

Addictive disorders are among the most common and debilitating psychiatric disorders in Europe. Despite the development of various evidence based treatments over the past decades, still about 50% of patients relapse within one year of treatment. Recent advances in understanding the neurobiological underpinnings of addictive behaviors have identified several potential new treatment targets. Neuromodulation techniques open new ways to reach these specific treatment targets. Activation in midbrain structures can be modulated by placing an electrode deep in the brain, called Deep Brain Stimulation (DBS). Using Transcranial Magnetic Stimulation (TMS) activation in cortical brain areas can be modulated, by placing a coil over the scalp, mainly the prefrontal cortex. Finally, cortical brain activation can be modulated by Transcranial Direct Current Stimulation (TDCS), via a small electrical current running between two electrodes placed over the scalp. Modulation of brain activation holds the promis to improve treatment outcome in psychiatry, when applied in the right brain areas, in the right patient. Findings with these three neuromodulation techniques in addiction will be presented by leading experts in this field, including both basic science and clinical findings. Dr. Sabine Vollstaedt-Klein will talk about the application of TDCS in addictive behaviors. Dr. Maarten Belgers will share findings of a recently conducted randomized controlled trial with TMS in patients with alcohol use disorder. Dr. Arnt Schellekens will discuss the role of TMS in the treatment of addictive behaviors with co-occurring mood disorders. Dr. Jens Kuhn will share his findings applying DBS in patients with alcohol use disorder.

Date :
April 8th, 2019

Cannabis and the Brain: an Update for Psychiatrists, at EPA 2019

Cannabis and the Brain: an Update for Psychiatrists, at EPA 2019
Description :

JS007: Measuring Quantity Matters: the Need for a Standard Joint Unit

A. Gual1, H. Lopez1, M. Balcells1.
1Neurosciences Institute. Hospital Clínic. IDIBAPS, Addictions Unit. Psychiatry Department, Barcelona, Spain.

JS008: Is it Possible to Measure Brain Disfunction in Cannabis Use Disorders? The Visomotor Rotation Task as a Biomarker of Cerebellum Alterations

L. Miquel1.
1Addiction Unit Hospital Clínic of Barcelona. IDIBAPS, Psychiatry. ICN, Barcelona, Spain.

JS009: Heavy Long-Term Cannabis Use: the Neurocognitive Effects

J. Cousijn1.
1University of Amsterdam, Psychology, Amsterdam, The Netherlands.

JS010: The CANDIS Program, a Validated Intervention to Treat Cannabis Use Disorders

E. Hoch1.
1Ludwig Maximilian University, Department of Psychiatry, Munich, Germany.

Partners :

European Federation of Addiction Societies (EUFAS)

Date :
April 8th, 2019

Introduction to Shared Decision-Making Combined with Motivational Interviewing, at EPA 2019

Introduction to Shared Decision-Making Combined with Motivational Interviewing, at EPA 2019
Description :

During the past several decades, patients’ values, preferences, and experiences have been given increasing emphasis in clinical interactions in an effort to promote patient-centered care. Patient-centered care has been found to be associated with improved patient outcomes, including improved self-management, patient satisfaction, and medication adherence, and some studies have found evidence for improved clinical outcomes. Both shared decision making and motivational interviewing focus on engaging patients to explore their views and opinions, including options for treatment or management approaches from the patients’ perspective. Although traditionally these methods have been applicable in distinct and nonoverlapping situations, practitioners may benefit from drawing on both approaches to maintain a patient-centered orientation in real-world clinical situations. In this introduction we provide guidance for how to apply patient-centered approaches across a range of clinical problems. We will explore the definitions of shared decision making and motivational interviewing and summarize the evidence on their use. We also consider the overlap between the 2 approaches and discuss and practice how practitioners can flexibly combine them to improve their patient-centered practice. The presentation will adapt to a non-native English speaking audience.

Date :
April 9th, 2019

annual network meeting for members, at EPA 2018

annual network meeting for members, at EPA 2018
Description :

MEETING SECTION ADDICTION PSYCHIATRY OF EPA

Meeting attended by:

albert batalla (albert.batallacases@radboudumc.nl),  arnt schellekens (secretary, arnt.schellekens@radboudumc.nl), falk kiefer (co-chair, falk.kiefer@zi-mannheim.de), geert dom (chair, geert.dom@uantwerpen.be), John Saunders (mail@jbsaunders.net), Eva Debusscher (ecva.debusscher@sjp.be), Frieda Matthys (frieda.matthys@vad.be), Wim vd Brink (w.vandenbrink@amc.uva.nl), Antoni Gual (tgual@clinic.cat), Karl Mann (karl.mann@zi-mannheim.de), Frank ten Wolde (f.tn.wolde@gmail.com), Marcin Wojnar (marcin@wum.edu.pl), Niel Merckx (niel.merckx@gmail.com), Konstantinos Rantis (radidinu@hotmail.com) 

Agenda:

1. welcome by chair:

Prof. Dr. Geert Dom welcomes everybody to the meeting. Thanks all attendees to have come to the meeting. After the introduction by the chair there is a short round of introduction of all participants of the meeting. We are happy with the large attendance of the section meeting and coverage of addiction topics at EPA 2018.

2. message from the chair:

-connect with addiction sections and societies through news-letter of EPA

-connect with EUFAS, joint symposium at EPA

-approval minutes Florence section meeting

3. planning of future activities:

In 2019 the EPA conference will be held April 6-9, in Warsaw. Deadline for submission is May 15th. The chair invites all participants of the meeting to share ideas on potential topics of interest.

Topic suggestions: theme transition psychiatry 

  1. workshop on neuromodulation smaller format: Falk Kiefer and Arnt Schellekens
  2. workshop on comorbidity internalizing/externalizing/suicide smoking and psychiatry Geert, Albert
  3. course (3 hours)/workshop comorbidity: requires additional preparation (paid) on four comorbidities ADHD/mood/anxiety: Albert, Geert, Arnt takes the lead

-MOOCS online courses on CBT, suggestion to make one on MI

4. symposium on cannabis and psychiatry (diagnostics, cessation, synthetic cannabis, comorbidity, epidemiology, policy acetylcysteine) Anthoni Gual and Wim van den Brink takes the lead

5. symposium or workshop older age and addiction: Frank Ter Wolde en Geert Dom with section older age psychiatry take the lead

6. co-hosting symposium WHO brief interventions in eastern Europe or ICD-11/DSM-5 Vladimir Poznyak (WHO), Marcin will contact him. Dzmitry Krupchanka (early career psychiatrist) Geert will contact him.

7. plenary speakers report on attendance in sessions/plenary as an argument for sessions in program

suggested speakers: on pain/opioids from eastern European country. Lituania:  sidharta? Russia:  Kacinski? Rehm Jurgen? Substance use related harm. Addiction from east to west… 

4. Varia & closure

closure by Falk Kiefer, thanks to all the attendees.  

Date :
05/03/2018

EPA 2018, Nice

EPA 2018, Nice
Description :

Symposium

ADHD and addiction, towards a consensus

Date :
March 4th, 2018

EPA 2018, Nice

EPA 2018, Nice
Description :

Chronic pain and risk of addiction

Date :
March 5th, 2018

EPA 2018, Nice

EPA 2018, Nice
Description :

Behavioural addictions: motivations and classification updates

Date :
March 6th, 2018

EPA 2018, Nice

EPA 2018, Nice
Description :

From new psychotropic drugs to psychodelic medicine: risks and challenges of research chemicals in psychiatry

Date :
March 6th, 2018

EPA Nice, 2018

EPA Nice, 2018
Description :

Co-occurring substance use and psychiatric disorders: pathogenesis and treatment

Partners :

European Federations of Addiction Societies (EUFAS)

Date :
March 6th, 2018

Calendar of Future Activities

Activities in the frame of the EPA Congress 2019:

Activities in the frame of the EPA Congress 2019:
Desciption :
  • Course: ECP Clinical Case Discussion: Alcohol Use Disorders, april 7th, 2019
  • Workshop: Treatment of Comorbid Psychiatric Disorders: How Do We Deal With Addiction?, pril 7th, 2019
  • Symposium: New Treatment Targets in Addiction Psychiatry: Translating Neuromodulation to the Clinic, april 8th 2019
  • Symposium: Cannabis and the Brain: an Update for Psychiatrists, april 8th 2019
  • Course: Introduction to Shared Decision-Making Combined with Motivational Interviewing, april 9th 2019